BioCryst Pharmaceuticals Inc (BCRX)
BioCryst Pharmaceuticals Inc. is a biotechnology company focused on discovering, developing, and commercializing specialty pharmaceuticals for the treatment of rare and infectious diseases. The company primarily develops oral medicines that inhibit specific enzymes involved in disease processes, with a key focus on antiviral and immune modulatory therapies.
Company News
BioCryst will present four abstracts at the ACAAI Annual Scientific Meeting, focusing on pediatric hereditary angioedema (HAE) research, including long-term prophylaxis data for ORLADEYO in children aged 2 to <12 years and psychosocial impact studies.
BioCryst Pharmaceuticals announced it will acquire Astria Therapeutics for $700 million, adding a new product candidate (Navenibart) for hereditary angioedema treatment, with the deal expected to close in Q1 2026.
BioCryst Pharmaceuticals reported record Q2 2025 revenue of $163.4 million, achieving its first significant GAAP net profit. ORLADEYO prescription drug sales grew 45% year-over-year, driving strong financial performance and positioning the company for continued growth in rare disease treatments.
BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?